Glyphosate Vedotin for Treatment of Bone Metastatic Castration-Resistant Prostate Cancer
Abstract
When prostate cancer is confined within the prostate, surgery or radiation therapy will cure almost all of them. When prostate cancer spreads to the lymph nodes or other organs, it is treated by androgen ablative therapy including drugs or surgery. However, the tumors eventually re-grow and become so called castration-resistant prostate cancer (CRPC) in about 2 years. Bone metastatic CRPC causes severe pain, pathologic fracture, spinal cord compression and paralysis, impairment of the quality of life, and eventual death. However, there is no effective treatment available for bone metastatic CRPC. In this project, we propose to create a new drug and test its selective anti-cancer effects in the cultured prostate cancer cell lines (Specific Aim 1) and in the bone tumor animal models that mimic human bone metastatic CRPC (Specific Aim 2). This drug is a conjugation of glyphosate (with a phosphate group that we predict will bind to calcium in the bone matrix, thus enriching the compound in the bone) and a toxin Vedotin (chemical name is monomethyl auristatin E, MMAE).
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2015
- Accession Number
- ADA621387
Entities
People
- Zongbing You
Organizations
- Tulane University of Louisiana